Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Can Anything Contain Drug Costs in the U.S.?

Lisa Rapaport  |  August 23, 2016

(Reuters Health)—The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue. Although brand-name drugs account for only 10% of all dispensed prescriptions in the U.S., they make up 72% of drug spending,…

Filed under:Drug Updates Tagged with:costsDrugsgeneric drugspharmaceutical companyPharmaceutical Research

HIPAA Audit Activities Increase in 2016

Kelly Tyrrell  |  August 17, 2016

In the coming months, rheumatologists may want to pay particular attention to their email inboxes. By the end of the year, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) will complete stage I, phase II of a series of desk and on-site audits designed to assess providers and their business…

Filed under:Practice SupportProfessional Topics Tagged with:HIPAA auditHIPAA complianceOffice for Civil Rights

FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2016

FDA advisory committees recommend the approvals of the abuse-deterrent opioid morphine sulfate for pain and brodalumab for plaque psoriasis…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationmorphine sulfateOpioidsPainplaque psoriasis

Most Seniors Won’t Abuse Opioids After Surgery

Andrew M. Seaman  |  August 13, 2016

(Reuters Health)—Seniors who receive prescriptions for opioid drugs to control pain after major surgery don’t usually end up addicted to them, research from Canada shows. One year after having major surgery, less than 1% of patients over age 66 were still taking opioids, according to a report in JAMA Surgery. Recent research has suggested the…

Filed under:AnalgesicsDrug Updates Tagged with:AddictionelderlyOpioidsPainPain Managementseniorsurgery

Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

Martin Garber, DO  |  August 12, 2016

When uric acid becomes elevated in the human body, a variety of problems can develop, most notably gout—a painful, inflammatory arthritis caused by uric acid crystal deposition in joints. Chronically elevated uric acid can also lead to painful kidney stones. The majority of patients found to have hyperuricemia, however, never go on to develop gout…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:ArthritisdiabetesGouthypertensionhyperuricemiaResearchrheumatologyriskTreatmentUric acidvascular disease

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Michele B. Kaufman, PharmD, BCGP  |  August 11, 2016

Cross Reactions A recent study published online in March in the Annals of the Rheumatic Diseases investigated if the infliximab biosimilar (CT-P13, infliximab-dyyb), which is marketed in Europe as Inflectra and Remsima, can be safely and effectively substituted for infliximab (Remicade).1 Infliximab and its biosimilar are manufactured via the same process. Researchers set out to…

Filed under:Biologics/DMARDsConditionsDrug Updates Tagged with:AntibodiesBiologicsDisease-modifying antirheumatic drugs (DMARDs)drugFDAinfliximabRheumatoid arthritisrheumatologySafetytherapyTreatmentupdate

garagestock/shutterstock.com

E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis

Michelle Burda, MLS, & Terence Starz, MD  |  August 11, 2016

A 52-year-old woman comes to the office complaining of a two-month history of pain and swelling in the small joints of her hands, feet and knees. She says, “Doctor, I’ve been searching the Internet, and I think I have rheumatoid arthritis. I have some questions for you.” The healthcare system in the U.S. is changing…

Filed under:ConditionsResearch RheumTechnology Tagged with:ArthritisInternetonlinepatient carepatient communicationResearchRheumatic DiseaserheumatologistrheumatologyTechnologytelehealthtelemedicine

New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal

Larry Beresford  |  August 11, 2016

SAN FRANCISCO—Considerable progress has been made in the treatment and management of rheumatoid arthritis (RA) in the past two decades, with rheumatologists now able to manage the effects of this chronic, debilitating condition for most of their patients, according to Ronald van Vollenhoven, MD, director of the Amsterdam Rheumatology and Immunology Center (ARC) in the…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:California Rheumatology Alliance 2016ResearchRheumatoid arthritisrheumatologistTreatment

New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis

Susan Bernstein  |  August 10, 2016

Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…

Filed under:ConditionsResearch Rheum Tagged with:criteriaDiagnosisJuvenile idiopathic arthritismacrophage activation syndromepatient careResearchrheumatologistrheumatologyTreatment

Importance of Oral Health, Mouth-Body Connection to Rheumatic Diseases Highlighted

Catherine Kolonko  |  August 10, 2016

Look inside the oral cavity of a patient for answers that go beyond what we perceive as the dentist’s domain. So goes the thinking of medical professionals interested in how oral health and bacteria-driven disease, such as periodontitis, may be linked to rheumatic disease, especially rheumatoid arthritis (RA). Bad bacteria that live in the mouth…

Filed under:ConditionsEducation & TrainingPractice SupportResearch Rheum Tagged with:connectionmouthoral healthResearchRheumatic Diseaserheumatologist

  • « Previous Page
  • 1
  • …
  • 205
  • 206
  • 207
  • 208
  • 209
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences